XML 31 R14.htm IDEA: XBRL DOCUMENT
v3.25.2

Supplemental Equity and Accumulated Other Comprehensive Income (Loss) Information | 12 Months Ended
--- | ---
Jun. 30, 2025
Notes to Financial Statements |
Supplemental Equity and Accumulated Other Comprehensive Income (Loss) Information | Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (Loss) Information: Equity The Company has declared cash dividends per share of $0.32 in fiscal 2025, 2024, and 2023. During fiscal 2025, 2024, and 2023, the Company repurchased 4,550,195 shares at an average share price of $60.60, 1,397,471 shares at an average share price of $57.28, and 222,000 shares at an average share price of $88.12, respectively. The Company’s accounting policy is to record the portion of share repurchases in excess of the par value entirely in retained earnings. In fiscal 2025, the Company incurred $1.8 million in excise tax from the share repurchase that was recorded in additional paid-in capital. During fiscal 2025, 2024 and 2023, the amounts within the Consolidated Statements of Shareholders’ Equity for the surrender and retirement of stock to exercise options due to net settlement stock options exercises, restricted stocks vesting, and restricted stock units vesting were $6.5 million, $21.9 million, and $28.9 million, respectively. Accumulated Other Comprehensive Income (Loss) The components of Other comprehensive income (loss) consist of changes in foreign currency translation adjustments and changes in net unrealized gains (losses) on derivative instruments designated as cash flow hedges. ​ Changes in Accumulated other comprehensive income (loss) attributable to Bio-Techne by component (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Unrealized | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Gains | ​ | Foreign | ​ | ​ | ​
​ | ​ | (Losses) on | ​ | Currency | ​ | ​ | ​
​ | ​ | Derivative | ​ | Translation | ​ | ​ | ​
​ | ​ | Instruments |  | Adjustments |  | Total
Balance as of June 30, 2022, net of tax | ​ | $ | 8,069 | ​ | $ | (83,269) | ​ | $ | (75,200)
Other comprehensive income (loss), before tax, attributable to Bio-Techne: : | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amounts before reclassifications (1) | ​ | ​ | 1,340 | ​ | ​ | 4,191 | ​ | ​ | 5,531
Amounts reclassified out | ​ | ​ | 4,526 | ​ | ​ | 152 | ​ | ​ | 4,678
Total other comprehensive income (loss), before tax, attributable to Bio-Techne: | ​ | ​ | 5,866 | ​ | ​ | 4,343 | ​ | ​ | 10,209
Tax expense | ​ | ​ | (1,073) | ​ | ​ | — | ​ | ​ | (1,073)
Total other comprehensive income (loss), net of tax, attributable to Bio-Techne: | ​ | ​ | 4,793 | ​ | ​ | 4,343 | ​ | ​ | 9,136
Balance as of June 30, 2023, net of tax(2) | ​ | $ | 12,862 | ​ | $ | (78,926) | ​ | $ | (66,064)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other comprehensive income (loss), before tax: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amounts before reclassifications | ​ | ​ | (12,632) | ​ | ​ | (9,941) | ​ | ​ | (22,573)
Amounts reclassified out | ​ | ​ | 10,317 | ​ | ​ | 3,210 | ​ | ​ | 13,527
Total other comprehensive income (loss), before tax | ​ | ​ | (2,315) | ​ | ​ | (6,731) | ​ | ​ | (9,046)
Tax expense | ​ | ​ | (2,445) | ​ | ​ | (761) | ​ | ​ | (3,206)
Total other comprehensive income (loss), net of tax | ​ |  | (4,760) | ​ | ​ | (7,492) | ​ | ​ | (12,252)
Balance as of June 30, 2024, net of tax(2) | ​ | $ | 8,102 | ​ | $ | (86,418) | ​ | $ | (78,316)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other comprehensive income (loss), before tax: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amounts before reclassifications | ​ | ​ | (12,011) | ​ | ​ | 21,895 | ​ | ​ | 9,884
Amounts reclassified out | ​ | ​ | 8,448 | ​ | ​ | 2,761 | ​ | ​ | 11,209
Total other comprehensive income (loss), before tax | ​ | ​ | (3,563) | ​ | ​ | 24,656 | ​ | ​ | 21,093
Tax expense | ​ | ​ | (2,003) | ​ | ​ | (654) | ​ | ​ | (2,657)
Total other comprehensive income (loss), net of tax | ​ |  | (5,566) | ​ | ​ | 24,002 | ​ | ​ | 18,436
Balance as of June 30, 2025, net of tax(2) | ​ | $ | 2,536 | ​ | $ | (62,416) | ​ | $ | (59,880)
(1) | Amounts before reclassifications related to foreign currency translation adjustments in the table above includes the amount attributable to Bio-Techne and excludes the $33 thousand attributable to the non-controlling interest in Eminence as of June 30, 2023.
(2) | The Company had a net deferred tax liability for its cash flow hedge of $0.8 million, $2.5 million, and $4.0 million as of June 30, 2025, 2024 and 2023.
Income taxes are not provided for foreign translation relating to permanent investments in international subsidiaries, but tax effects within foreign currency translation adjustments do include impacts from the net investment hedge.

X
- Definition The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/220/tableOfContent + Details
Name: | us-gaap_ComprehensiveIncomeNoteTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration